268 results about "Glucose blood" patented technology

The application discloses a blood sugar management applet with home support function. A data acquisition interaction module is connected with an external blood glucose meter device through a Bluetooth communication protocol to collect blood sugar data of a user in real time; a home collaborative management module realizes safe sharing of blood sugar data of the user among family members, and the family members can check relevant blood sugar data, diet and exercise records through the applet end; and an intelligent analysis and reminding module is based on an LSTM neural network model, performs trend analysis on historical blood sugar data after a risk early warning trigger, generates personalized health reminding information automatically in combination with preset rules, and sends the information to the user and associated family members in a multi-modal form. The application effectively improves the blood sugar management efficiency of patients, reduces the risk of data leakage, and can significantly reduce the fasting blood sugar value and the 2-hour postprandial blood sugar value of patients compared with the prior art, reduces the cost of manual intervention, and has significant clinical application value and social and economic benefits.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The application discloses a novel multifunctional resistant starch rich in active small-molecule ternary complex, a one-step induction synchronous preparation process and application thereof. By introducing lipids with a certain structure, phenolic compounds without long alkyl chains and starch form inclusion complexes with V-shaped ordered structures. By adjusting the addition sequence of lipids and phenolic compounds in the preparation process and optimizing the process parameters, multifunctional resistant starch with high phenolic loading rate and strong antioxidant activity is prepared by one-step induction. The application breaks through the technical bottleneck that phenolic compounds without long alkyl chains are difficult to form V-shaped complexes with starch, significantly improves the complexing efficiency of starch and phenolic compounds without long alkyl chain structure, and improves the content of active small-molecule phenols in the complex. Compared with the prior art, the prepared complex has stronger DPPH free radical scavenging effect, shows better digestion resistance and antioxidant effect, and can be used in the fields of functional food, nutritional additives and the like for reducing postprandial blood glucose, antioxidant and the like.

The application provides a self-calibration circuit and method of a dynamic blood glucose monitoring chip. It relates to the field of dynamic blood glucose monitoring, and solves the problem of error caused by the input offset of the operational amplifier which cannot be calibrated. The circuit comprises a digital-to-analog converter which transmits a first voltage value to the positive input end of a first operational amplifier and transmits a second voltage value to the positive input end of a second operational amplifier; the output end of the first operational amplifier is connected to the counter electrode of a sensor; the reference electrode of the sensor is connected to the negative input end of the first operational amplifier, and the working electrode of the sensor is connected to the negative input end of the second operational amplifier; the output end of the second operational amplifier is transmitted to a first analog-to-digital converter, and the second end of the first analog-to-digital converter is accessed through a cross resistance. The application can calibrate the error caused by the input offset of the operational amplifier, the error caused by the drain current of all MOS tubes on the signal link, and the resistance value of the pre-operational amplifier circuit.

The images related to this design are used, for example, to monitor, display, or track measurement data such as blood glucose levels, as well as exercise, insulin administration, and food intake. These images can be operated by tapping, pressing, swiping, or scrolling the display screen, or via other devices associated with the display device.

This invention discloses an integrated enzyme-free SERS microneedle sensor for real-time glucose monitoring and its fabrication method, belonging to the fields of biosensing and nanophotonics technology. The sensor comprises an optically transparent polymer microneedle array, a polydopamine intermediate layer and a gold nanostructure layer sequentially modified on its surface, and glucose-specific recognition molecules immobilized on the surface of the gold nanostructure layer. This invention employs a single-layer integrated structure, integrating transdermal puncture, laser conduction, SERS enhancement, and glucose recognition functions, eliminating the need for multi-layer stacking and enabling accurate quantitative detection of glucose under enzyme-free conditions. The sensor fabrication process is simple and controllable, requiring no complex equipment, allowing for mass production at a low cost, and has broad application prospects in the field of minimally invasive blood glucose monitoring devices, meeting the needs for real-time, accurate, and minimally invasive blood glucose monitoring.

This invention provides a ready-to-eat convenience food made from whole colored potatoes and its preparation method. The raw materials of the ready-to-eat convenience food include the following components: colored potatoes, wheat flour, rice flour, corn flour, soybean flour, lotus root powder, wheat gluten, eggs, milk powder, modified vitamin C, citric acid solution, modified sucrose ester, granulated sugar, and baking soda. Compared with existing ready-to-eat grain foods, this invention uses fresh whole colored potatoes as the main ingredient, combined with various grain crops as raw materials, and incorporates wheat gluten, lotus root powder, eggs, and milk powder to construct a complete nutritional complex formula system in which carbohydrates, high-quality protein, and various micronutrients coexist synergistically, thus possessing the aroma and nutrition of various major grain crops such as potatoes, rice, wheat, beans, and corn. Simultaneously, this invention employs a non-frying processing method combining steaming and low-temperature drying, avoiding the destruction of nutrients caused by high-temperature frying, which helps retain natural anthocyanins and other antioxidant active substances, improving the overall antioxidant capacity of the product, and demonstrating good blood sugar control and anti-aging effects at the nutritional level.

1. The name of the design product: blood glucose meter (RAK662). 2. The use of the design product: the design product is used for measuring blood glucose level. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The application provides a clinical marker screening method and system after metabolic response typing and application. Specifically, according to the change of metabolic indexes of normal weight people and overweight / obese people before and after meals, three clusters based on respiratory quotient (RQ) are found; the fasting fat oxidation capacity, postprandial metabolic response and postprandial blood glucose response of people belonging to different clusters also have different dynamic change patterns. In addition, key biomarkers distinguishing the three clusters are also found; the prediction model constructed by using the key biomarkers can accurately divide the subjects into three RQ clusters and can be used for predicting the results of weight loss intervention and life intervention guidance. The system constructed according to the clinical markers of the application has high sensitivity and accuracy, the indexes used are easy to obtain, and has good clinical application prospect.

The application relates to the technical field of drug efficacy prediction, in particular to a multi-modal data prediction model for diabetes gene therapy response, which comprises an unmedicated data collection module, a medicated data collection module and a data prediction module.The unmedicated data collection module collects unmedicated data samples of a user; the medicated data collection module collects data samples of the user after taking medicine; the data samples comprise explicit data and implicit data; the explicit data is body information and medicine information related to blood glucose change; and the implicit data is blood glucose values corresponding to the explicit data; the data prediction module inputs fused features into a convolutional network model to generate drug efficacy prediction values.The application generates a prediction residual corresponding to the explicit data after taking medicine through a blood glucose value prediction module, identifies blood glucose fluctuation characteristics caused by non-drug factors by using the prediction residual, separates the net influence of medicine on blood glucose, and thus improves the accuracy of drug efficacy prediction.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

A wearable device for measuring blood glucose and blood pressure for a user includes a main body including a first side and a second side formed on the opposite side of the first side; a first supporting frame protruding from the first side and a second supporting frame protruding from the second side; a belt portion having a first belt end detachably coupled to the first supporting frame, a second belt end detachably coupled to the second supporting frame, and at least one aligning mark, wherein the belt portion is positioned around a wrist of the user; wherein the main body includes at least one pressure sensor array assembly overlaid on a radial artery of the user; wherein the pressure sensor array assembly includes a plurality of apertures arranged one after another to form a cross-shaped pattern and at least four sensor elements arranged in a symmetrical configuration.

This invention provides a monitoring data processing method and system, belonging to the field of medical device technology. Specifically, it includes: determining the identification results of elimination targets within an electric field strength range based on a control optimization strategy; using the identification results of elimination targets and the changes in blood glucose monitoring data among patients with different monitoring needs within the electric field strength range, determining the available intensity range within the electric field strength range; and using the available intensity range data and the consistency of blood glucose monitoring data between different monitoring sensors of patients whose blood glucose monitoring data changes within the available intensity range meet the requirements, determining the monitoring processing strategy for different patients' blood glucose monitoring devices, thereby improving the accuracy and stability of blood glucose monitoring processing.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

The present invention relates to methods of improving glucose homeostasis and / or reducing glucose plasma levels by administering a SIRT6 activator. The present invention also provides methods for treating hyperglycemia, prediabetes, and diabetes including Type I diabetes, Type II diabetes or gestational diabetes by administering a SIRT6 activator.

The application discloses an integrated automatic blood-squeezing peripheral blood glucose detection device, which comprises a host computer (1) and a detachably connected disposable sterile integrated core (2). The disposable sterile integrated core (2) comprises a microneedle assembly (4), an elastic squeezing structure (3) arranged around the microneedle assembly (4), a blood glucose detection test paper (6), a capillary blood guiding channel (5) and an electrode contact (7). When the microneedle assembly (4) completes skin puncture, the elastic squeezing structure (3) applies synchronous micro mechanical squeezing force to the tissue around the blood sampling site, so that blood seeps out and is automatically transported to the blood glucose detection test paper (6) through the capillary blood guiding channel (5). The blood glucose detection test paper (6) is internally integrated in the disposable sterile integrated core (2), and the electrode contact (7) is used for electrical connection with the host computer (1). The application realizes the integration of blood sampling, automatic blood squeezing, blood guiding and detection by using a pure mechanical structure, and does not need manual blood squeezing and manual sample adding. The application has the advantages of simple structure, low cost, simple operation, safety and sanitation, and is suitable for rapid blood glucose detection in family and hospital scenes.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

1. The name of the design product: blood analyzer (SZH-MF03A). 2. The use of the design product: for testing the concentration of blood glucose, uric acid, hemoglobin in blood samples. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

1. Name of the product in this design: Blood glucose meter. 2. Purpose of this design: For testing blood glucose. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The utility model discloses a blood glucose monitoring device, including sensor carrier and launch carrier, sensor carrier includes first casing, probe module and sensor module, and the circumference of first casing is equipped with first buckle and the second clamping groove of opposite side of first buckle, launch carrier includes fourth casing and launch module, and the circumference of fourth casing is equipped with with first clamping groove and second buckle. Among them, first casing is sealedly connected with second casing, third casing respectively with adhesive mode, strengthens the sealing performance, prevents water, perspiration etc. and enters the casing, improves waterproof performance, prolongs the life, when needing to assemble, the second buckle is made into the second clamping groove to the oblique push launch carrier, then press down launch carrier and make first buckle enter first clamping groove, the blood glucose monitoring device is the loading state at this moment, when needing to disassemble, first buckle is broken outwards to first buckle and first clamping groove, second buckle and second clamping groove are separated, then launch carrier is taken out, the blood glucose monitoring device is the unloading state at this moment. The above structure design is simple and reasonable, and the operation of assembling and disassembling is simple, which can meet the sealing waterproof performance, and also can facilitate the user to assemble and disassemble the blood glucose monitoring device.

An insertion device configured to implant a first medical device and a second medical device in a user. The first medical device may be a fluid delivery cannula configured to deliver a fluid (e.g., insulin) to the user. The second medical device may be an analyte sensor (e.g., a glucose sensor) configured to detect a physiological characteristic of the user (e.g., a glucose level). The insertion device may be configured to be worn by the user. The insertion device includes a first linkage assembly configured to extend and retract a first insertion needle to implant the first medical device and a second linkage assembly configured to extend and retract a second insertion needle to implant the second medical device. The insertion device includes a user input device configured to cause the insertion device to initiate the implantation when activated by the user.

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The application discloses a kind of dynamic food nutrition loss and gain grade evaluation system and method based on food, food material (including herbal plant) ingredient content level and individual health data.System acquires food ingredient data (such as energy, protein, fat, cellulose, potassium, sodium, magnesium, additive, etc.) and individual medical index (such as blood sugar, blood pressure, blood fat, uric acid, height and weight, allergy history, etc.) data, combined with eu nutrition score standard and China's general coefficient, then dynamically adjusts coefficient weight according to individual health condition (such as high blood pressure user adjusts high iron sodium related coefficient), finally generates general health grade and personalized recommendation grade.System presents results through mobile terminal or PC terminal App, and uses encryption technology to protect user privacy.The application solves the problem of lack of individualization in existing evaluation, and provides accurate dietary health guidance for users.

The present invention belongs to the field of functional foods, and specifically relates to a composition for lowering glucose and stabilizing an insulin level, a preparation method therefor, and use thereof. The composition of the present invention comprises a component I and a component II. The component I is cyclodextrin and a derivative thereof, the component II is naringenin and a derivative thereof, and the mass ratio of the component I to the component II is (0.1-100):(0.01-1). After being eaten with a meal or added to food, especially high-carbohydrate food, the composition of the present invention can significantly maintain the stability of the insulin level in the body while significantly controlling the postprandial blood glucose level. Long-term use can achieve the effects of stabilizing triglyceride, low-density lipoprotein, and high-density lipoprotein levels.

1. The name of the design product: blood glucose meter (RAK660). 2. The use of the design product: the design product is used for measuring blood glucose level. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Techniques disclose herein relate to determining glucose reference sample times. The techniques may involve determining a first glucose reference sample measurement for a patient. The techniques may further involve determining timing information for obtaining a second glucose reference sample measurement based at least in part on readings from a continuous glucose sensor.

The application discloses a personalized closed-loop artificial pancreas system, which comprises a detection module (100) for continuously detecting blood glucose values of a patient, an infusion module (102) for infusing insulin into the patient, and a program module (101) for controlling the detection module (100) and the infusion module (102). The program module (101) generates insulin infusion instructions according to the blood glucose values detected by the detection module (100) and controls the infusion module (102) to perform infusion. The program module (101) comprises a user interface. In response to an input of the patient, the program module (101) executes a corresponding meal mode function. The meal mode comprises a high-carbohydrate mode and a normal-carbohydrate meal mode. According to the input of the patient, the program module (101) executes the function of the high-carbohydrate mode or the normal-carbohydrate mode, so as to be applicable to people with different carbohydrate consumption habits, improve the adaptability of the closed-loop artificial pancreas to different people, and enable people with different carbohydrate consumption habits to maintain a satisfactory blood glucose control effect.

The application discloses a preparation method and application of a composite strain of a sugar-controlling probiotic, and belongs to the technical field of microorganisms. The method comprises the steps of strain stock solution preparation, anaerobic culture, pH value determination and regulation, and composite strain proportioning. Through a dynamic shunting mechanism with pH value 4.3 as a threshold, the culture solution lower than the value is subjected to re-acidification treatment, and the culture solution higher than the value is subjected to differential dilution and coating operation. Finally, Lactobacillus gasseri, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Bifidobacterium breve, Bifidobacterium lactis and Bifidobacterium longum are mixed at a preset ratio, and a sustained-release agent is added for storage. The method can significantly improve the screening efficiency of target probiotics, the stability of the composite preparation and the blood glucose regulation effect, and can be widely applied to the development of sugar-controlling probiotic products.

The application discloses a breast reconstruction type recommendation system and method based on multi-modal data, relates to the technical field of breast reconstruction type recommendation, and aims to solve the technical problems of traditional operation type recommendation depending on linear superposition evaluation of a single index, being unable to quantize the nonlinear complex mechanism of metabolic and vascular injury, and leading to inaccurate risk evaluation and lack of targeted recommendation, the system comprising a feature calculation and analysis module, wherein the feature calculation and analysis module comprises a clinical information structured unit, a metabolic and vascular injury index calculation module, an image feature unit and a test feature unit. Through the metabolic and vascular injury index calculation module, the nonlinear normalization function, the standardization function, the interactive effect analysis algorithm and the Sigmoid function are integrated, the true risk difference between patients with short disease duration but poor blood glucose control and patients with long disease duration but good blood glucose control is effectively distinguished, the risk evaluation is more in line with the pathophysiological law, and a scientific quantitative basis is provided for operation type selection.